Early Development Services for Bioconjugates
With more than two decades of bioconjugation expertise, we empower startups and global pharma to accelerate development by accessing our fast and flexible workflows. Lonza customers benefit from our innovative technology platforms and a collaborative partnership that rapidly advance their novel bioconjugates to the next stage.
At Lonza Early Development Services for Bioconjugates we support customers throughout the entire bioconjugate development lifecycle, beginning with bioconjugate architecture design and initial process establishment, and continuing with optimization for scalable, robust performance. Our development services span all development stages, streamlining candidate selection and bioconjugates process development to align with therapeutic objectives. With deep technical expertise, we de-risk programs, accelerate functional assessment and evaluate manufacturability early.
Lonza customers benefit from
- High-throughput bioconjugate screening enabling rapid lead candidate identification
- An integrated platform combining advanced protein expression, drug-linker synthesis, and bioconjugation services
- Comprehensive analytical capabilities for robust characterization
- Deep scientific and regulatory pathway understanding
- Strategic guidance for biotechs: focused, milestone-driven preclinical development and partnerships that build investor confidence.
When leveraged early, these capabilities facilitate a smoother development path and accelerate the transition of your bioconjugate therapeutic to the clinic.
Lonza’s Early Development Services for Bioconjugates can help you define the overall bioconjugate architecture and select suitable conjugation approaches, considering product requirements and developability. Our high-throughput screening pipeline rapidly identifies optimal process conditions and enables the generation of a diverse panel of bioconjugate variants for in vitro and in vivo proof-of-concept studies.
For non-human in vivo studies requiring larger material supply (e.g. dose-range finding studies in non-human primates), we scale up to gram-level quantities using representative purification methods to support downstream development.
Lonza’s Early Development Services for Bioconjugates offers integrated, end-to-end expertise in bioconjugate development—from protein engineering and small molecule payload development to advanced conjugation strategies and formulation development. We leverage deep process and analytical know-how to develop tailored workflows for diverse bioconjugate modalities across diverse protein formats, payload classes and have experience with all the major conjugation technologies.
Lonza enables flexible customer entry at any stage of development—from early concept and preclinical design through process optimization, pilot batches, and GMP manufacturing—providing seamless transitions and technical support throughout the journey.
At Lonza, manufacturability and facility-fit are considered from the earliest development phase to avoid re-optimization and reducing the number of technology transfers, ultimately de-risking and streamlining the path to IND and commercialization. Lonza’s Early Development Services for Bioconjugates is part of an integrated platform that delivers end-to-end development, from preclinical discovery through to commercialization, covering all components, protein, payload linker, drug substance, and drug product, all within one Lonza.
Lonza CDMO bioconjugates – EDS bioconjugates provides early‑stage support to tailor bioconjugate development to your therapeutic needs and help streamline process development and manufacturing, enabling a smoother path toward clinical supply
Lonza offers an integrated early‑development offer across key bioconjugate components, including protein de‑risking and expression, payload supply, and bioconjugation, helping you reduce interfaces and speed decision‑making.
Yes. Lonza CDMO bioconjugates – EDS bioconjugates can generate a panel of bioconjugate variants for PoC work (typical outputs cited as ~10–20 mg per variant) and support scale‑up to gram quantities for studies such as animal work.
Lonza emphasizes early de‑risking and optimization, considering manufacturability and facility fit from the earliest phase to help avoid re‑optimization later. By reducing interfaces and tech transfers, the approach can de‑risk and streamline the path to IND and commercialization.
Yes. The EDS bioconjugates page highlights 20+ years’ experience and 100+ projects spanning from preclinical development to commercial scale, along with 400+ GMP batches per year referenced as evidence of scale and execution experience.
